Savara Inc Proceeds from Long-Term Debt Issued
Savara Inc (SVRA) reported Proceeds from Long-Term Debt Issued of $29.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-11
- Savara Inc proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $0.00.
- Savara Inc proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00.
- Savara Inc proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $0.00.
- Savara Inc proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $29.60M.
- Savara Inc proceeds from issuance of long-term debt for fiscal 2025 was $29.60M.
- Savara Inc proceeds from issuance of long-term debt for fiscal 2022 was $26.44M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $29.60M 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $29.60M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $29.60M 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $29.60M 10-Q · filed 2026-05-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 derived: sum of 2 quarters · filed 2024-03-07 | $26.44M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $26.44M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $26.44M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |